Induction of apoptosis by MCL-1 inhibitors in chronic lymphocytic leukemia cells.
作者信息
Chen Lisa S, Keating Michael J, Wierda William G, Gandhi Varsha
机构信息
Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
出版信息
Leuk Lymphoma. 2019 Dec;60(12):3063-3066. doi: 10.1080/10428194.2019.1622098. Epub 2019 Jun 4.
Abstract
摘要
相似文献
1
Induction of apoptosis by MCL-1 inhibitors in chronic lymphocytic leukemia cells.
Leuk Lymphoma. 2019 Dec;60(12):3063-3066. doi: 10.1080/10428194.2019.1622098. Epub 2019 Jun 4.
2
AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia.
Clin Cancer Res. 2020 Jul 15;26(14):3856-3867. doi: 10.1158/1078-0432.CCR-19-1397. Epub 2020 Jan 14.
3
Targeting MCL1, Companies Aim to Unblock Apoptosis.
Cancer Discov. 2019 May;9(5):572. doi: 10.1158/2159-8290.CD-ND2019-002. Epub 2019 Apr 3.
4
BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.
Cancer Cell. 2018 Dec 10;34(6):879-891. doi: 10.1016/j.ccell.2018.11.004.
5
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.
Blood. 2021 May 20;137(20):2721-2735. doi: 10.1182/blood.2020010167.
6
Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia.
Leukemia. 2019 Jul;33(7):1663-1674. doi: 10.1038/s41375-018-0364-x. Epub 2019 Jan 30.
7
Pathways and mechanisms of venetoclax resistance.
Leuk Lymphoma. 2017 Sep;58(9):1-17. doi: 10.1080/10428194.2017.1283032. Epub 2017 Jan 31.
8
The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia.
Crit Rev Oncol Hematol. 2016 Apr;100:32-6. doi: 10.1016/j.critrevonc.2016.02.003. Epub 2016 Feb 11.
9
From mitochondrial biology to magic bullet: navitoclax disarms BCL-2 in chronic lymphocytic leukemia.
J Clin Oncol. 2012 Feb 10;30(5):554-7. doi: 10.1200/JCO.2011.37.9339. Epub 2011 Dec 19.
10
Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
Oncotarget. 2015 Dec 29;6(42):44832-48. doi: 10.18632/oncotarget.6265.
引用本文的文献
1
Targeting MCL-1 protein to treat cancer: opportunities and challenges.
Front Oncol. 2023 Jul 31;13:1226289. doi: 10.3389/fonc.2023.1226289. eCollection 2023.
2
Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia.
Front Oncol. 2022 Feb 22;12:833714. doi: 10.3389/fonc.2022.833714. eCollection 2022.
3
AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia.
Clin Cancer Res. 2020 Jul 15;26(14):3856-3867. doi: 10.1158/1078-0432.CCR-19-1397. Epub 2020 Jan 14.
本文引用的文献
1
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
N Engl J Med. 2018 Mar 22;378(12):1107-1120. doi: 10.1056/NEJMoa1713976.
2
Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.
Signal Transduct Target Ther. 2017 Apr 7;2:17012. doi: 10.1038/sigtrans.2017.12. eCollection 2017.
3
DRP-1 is required for BH3 mimetic-mediated mitochondrial fragmentation and apoptosis.
Cell Death Dis. 2017 Jan 12;8(1):e2552. doi: 10.1038/cddis.2016.485.
4
Diffuse Large B Cell Lymphoma Cell Line U-2946: Model for MCL1 Inhibitor Testing.
PLoS One. 2016 Dec 1;11(12):e0167599. doi: 10.1371/journal.pone.0167599. eCollection 2016.
5
Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.
Mol Cancer Ther. 2016 Dec;15(12):3015-3027. doi: 10.1158/1535-7163.MCT-16-0017. Epub 2016 Oct 7.
6
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.
Nature. 2016 Oct 27;538(7626):477-482. doi: 10.1038/nature19830. Epub 2016 Oct 19.
7
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Lancet Oncol. 2016 Jun;17(6):768-778. doi: 10.1016/S1470-2045(16)30019-5. Epub 2016 May 10.
8
The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia.
Crit Rev Oncol Hematol. 2016 Apr;100:32-6. doi: 10.1016/j.critrevonc.2016.02.003. Epub 2016 Feb 11.
9
Small-Molecule and Peptide Inhibitors of the Pro-Survival Protein Mcl-1.
ChemMedChem. 2016 Apr 19;11(8):802-13. doi: 10.1002/cmdc.201500497. Epub 2015 Dec 23.
10
Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).
Blood Cancer J. 2015 Nov 13;5(11):e368. doi: 10.1038/bcj.2015.88.
Zotero 插件